PEAK

Healthpeak Properties, Inc.

Investor Moves

NameValueActionChangePriceLast Price
Ken GriffinCitadel Advisors
$15M916.2k shares
TrimQ1 2026
$66M
$16.43
$17.10
Paul Tudor Jones IITudor Investment
$3M165.7k shares
TrimQ1 2026
$29M
$16.43
$17.10
Jim SimonsRenaissance Technologies
$13M813.6k shares
AddQ1 2026
$4M
$16.43
$17.10
Baillie GiffordInvestor
$6M334.8k shares
TrimQ1 2026
$404k
$16.43
$17.10
Chris DavisDavis Selected Advisers
$11M645.2k shares
AddQ1 2026
$4M
$16.43
$17.10
Jefferies GroupInvestor
$-623.5K
ExitQ1 2026
$624k
--
$17.10

Congress Trades

NameValueActionAmount RangePriceLast Price
Michael McCaulRepublican
$175k
SellMar 23, 2026
$100k-$250k
--
$17.10
Gilbert CisnerosDemocrat
$8k
SellFeb 10, 2026
$1k-$15k
--
$17.10
Lisa McClainRepublican
$8k
SellAug 4, 2025
$1k-$15k
--
$17.10
Ro KhannaDemocrat
$8k
BuyJul 25, 2025
$1k-$15k
--
$17.10
Rob BresnahanRepublican
$8k
SellMay 15, 2025
$1k-$15k
--
$17.10
Julie JohnsonDemocrat
$8k
SellApr 1, 2025
$1k-$15k
--
$17.10

News

globenewswire.comPEAK:AIO and Los Alamos National Laboratory Launch Lattice - Breaking Open the Metadata Bottleneck in Parallel File Systemsglobenewswire.comJun 3globenewswire.comCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meetingglobenewswire.comMay 30globenewswire.comCogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meetingglobenewswire.comApr 21